ATG is an anti-thymocyte globulin with immunosuppressive activity used for the prevention and treatment of organ rejection, for the treatment of hormone-resistant graft-versus-host disease, and for the treatment of aplastic anemia.
ATG has immunosuppressive activity, possibly by removing the inhibitory effect of suppressor T lymphocytes on bone marrow hematopoiesis.
ATG should not be used in pregnant women, people suffering from acute or severe infections, and is also contraindicated in people who are allergic to the components of the drug. Adverse reactions to ATG include fever, abdominal pain, constipation, diarrhea, nausea, anemia, headache, myalgia, rash, and in severe cases, leukopenia and thrombocytopenia.
The use of ATG should be strictly controlled by the indications and under the guidance of hematologists.